PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate differences in the incidence of enteropathy or intestinal malabsorption in patients taking angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), and beta blockers (BBs) at a single center in Korea.
METHODS: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021.
RESULTS: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p=0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p=0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p=0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p=0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities.
CONCLUSIONS: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs.
METHODS: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021.
RESULTS: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p=0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p=0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p=0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p=0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities.
CONCLUSIONS: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs.
摘要：
目的：研究服用血管紧张素II受体阻滞剂（ARB）的患者肠病或肠道吸收不良发生率的差异，血管紧张素转换酶抑制剂（ACEI），钙通道阻滞剂（CCB），和β受体阻滞剂（BBs）在韩国的一个中心。
方法：在这项回顾性研究中，我们利用来自杨山电子病历的数据来识别129,169例患者.这些人被处方为奥美沙坦，其他ARB，ACEI,CCB,2008年11月至2021年2月之间的BB。
结果：在44,775名患者中，观察到51例（0.11％）患有肠病或肠道吸收不良。与ACEI组相比，肠病和肠道吸收不良的校正比值比（ORs）为OR=1.313（95％置信区间[CI]：[0.188-6.798]，p=0.893)对于奥美沙坦，OR=0.915（95%CI：[0.525-1.595]，p=0.754)对于其他ARB，对于CCB，OR=0.928(95%CI：[0.200-4.307]；p=0.924)，对于BBs组，OR=0.663(95%CI：[0.151-2.906]；p=0.586)。这些发现根据年龄等因素进行了调整，性别,降压药物的持续时间，和合并症。
结论：在一项对服用抗高血压药物的患者进行的回顾性队列研究中，当ACEI与奥美沙坦相比时，肠病或肠道吸收不良的发生率没有显着差异，其他ARB，CCB,和BB。
方法：在这项回顾性研究中，我们利用来自杨山电子病历的数据来识别129,169例患者.这些人被处方为奥美沙坦，其他ARB，ACEI,CCB,2008年11月至2021年2月之间的BB。
结果：在44,775名患者中，观察到51例（0.11％）患有肠病或肠道吸收不良。与ACEI组相比，肠病和肠道吸收不良的校正比值比（ORs）为OR=1.313（95％置信区间[CI]：[0.188-6.798]，p=0.893)对于奥美沙坦，OR=0.915（95%CI：[0.525-1.595]，p=0.754)对于其他ARB，对于CCB，OR=0.928(95%CI：[0.200-4.307]；p=0.924)，对于BBs组，OR=0.663(95%CI：[0.151-2.906]；p=0.586)。这些发现根据年龄等因素进行了调整，性别,降压药物的持续时间，和合并症。
结论：在一项对服用抗高血压药物的患者进行的回顾性队列研究中，当ACEI与奥美沙坦相比时，肠病或肠道吸收不良的发生率没有显着差异，其他ARB，CCB,和BB。
